Prolia

Type: Product
Name: Prolia
First reported Jul 25 2014 - Updated 3 hours ago - 1 reports

Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 Second Quarter Financial Results

/PRNewswire/ — Amgen (AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and ... [Published Jutia Group - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 1 reports

Ultragenyx Appoints Sunil Agarwal, M.D. as Chief Medical Officer and Senior Vice President

(GLOBE NEWSWIRE) -- . (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Sunil Agarwal, M.D. as its Chief Medical Officer and Senior Vice President, ... [Published EMoneyDaily - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 24 2014 - 2 reports

GlaxoSmithKline slashes forecast as 2nd-qtr sales and earnings fall sharply

UK pharma giant GlaxoSmithKline (LSE: GSK) saw its shares fall 3.9% to £45.94 shortly after the company reported disappointing second-quarter 2014 financial results, and chief executive Sir Andrew Witty admitted that "it is now unlikely that we will deliver ... [Published Pharma Letter - Jul 24 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Human medicines European public assessment report (EPAR): Prolia, denosumab, Revision: 5, Authorised

Entities: Prolia, Denosumab
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

A Real Dividend Growth Machine: Q2 2014 Review

Summary Second-quarter review of actual results from a real dividend growth stock portfolio. Discussion of recent portfolio decisions and outlook for the third quarter. Comprehensive example of how a young dividend growth investor manages his portfolio. ... [Published Seeking Alpha - Jul 08 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

Large-cap biotech stocks should see healthy second-quarter results driven by strong demand and new products, a Citi analyst said Thursday.Performance of the sector will look especially attractive in light of a weak first quarter, when the sector was held ... [Published Benzinga.com - Jul 03 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Global Osteoporosis Market & Drugs Analysis

Dallas, TX -- ( SBWIRE ) -- 07/02/2014 -- Osteoporosis is often called the "silent disease" because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility ... [Published SBWire - Jul 02 2014]
Entities: Osteoporosis, Prolia, Drugs
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Winners of the inaugural Creative Floor Awards revealed

In a relatively low-key event in Shoreditch last night, the winners of a new creative pharma marketing award were revealed. are the only healthcare awards to donate a percentage of profits to help young talent break into the health and wellness industry, ... [Published Pharma Times - Jul 02 2014]
First reported Apr 30 2014 - Updated May 01 2014 - 1 reports

1st Quarter Results

RespiratoryQ1 2014 (£1,554 million; down 11%)Respiratory sales in the quarter declined 11% to £1,554 million.  Seretide/Advair sales were down 15% to £1,039 million, Flixotide/Flovent sales decreased 2% to £193 million and Ventolin sales grew 15% to ... [Published TrustNet - Apr 30 2014]
First reported Apr 23 2014 - Updated Apr 23 2014 - 1 reports

Amgen's net earnings dips by 25% to $1,073 million in Q1

Amgen Inc. has posted lower net profit of $1,073 million during the first quarter ended March 2014 as against $1,434 million in the corresponding period of last year. Its total revenues increased by 7 per cent to $4,521 million from $4,238 million.The ... [Published PharmaBiz - Apr 23 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Patent expiration, stagnant R&D spend seriously affect blockbuster sales of big pharma during 2007-2013

Patent expiration of several blockbusters and limited success in launching new molecules during the last few years are the two critical factors that  impacted the revenues of the top international pharmaceutical companies during the period 2007-2013. ... [Published PharmaBiz - Mar 28 2014]
First reported Feb 15 2014 - Updated Feb 15 2014 - 1 reports

Prolia - Insurance

My husband and I are moving to the Tampa Bay, FL, area and I am insurance shopping. So far Humana has a couple plans that could work. Does anyone have experience with Humana paying for or not paying for Prolia injections? ... [Published HealthBoards - Feb 15 2014]
Entities: Prolia, Humana Inc

Quotes

...On a conference call to discuss the results, Sir Andrew said: "I remain very concerned about allegations concerning our China business. The situation is complicated and difficult and while the investigation is active, there is little I can add."
...Agarwal. "To develop novel therapies for these patients who have no approved treatments and to help push the science forward in these rare genetic diseases is something I am thrilled to be a part of."
...growth in adjusted operating income make us confident in our full-year growth outlook," said Robert A Bradway, chairman & chief executive officer. "We continue to advance our robust late stage pipeline and expect to submit global filings for evolocumab in 2014."

More Content

All (17) | News (15) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen A... [Published Jutia Group - Jul 25 2014]
GlaxoSmithKline slashes forecast as 2nd-qtr sal... [Published Pharma Letter - Jul 24 2014]
Ultragenyx Appoints Sunil Agarwal, M.D. as Chie... [Published EMoneyDaily - Jul 23 2014]
Half Yearly Report [Published TrustNet - Jul 23 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 11 2014]
A Real Dividend Growth Machine: Q2 2014 Review [Published Seeking Alpha - Jul 08 2014]
Citi Sees Plenty Of Q2 Earnings Beats Ahead In ... [Published Benzinga.com - Jul 03 2014]
Global Osteoporosis Market & Drugs Analysis [Published SBWire - Jul 02 2014]
Winners of the inaugural Creative Floor Awards ... [Published Pharma Times - Jul 02 2014]
1st Quarter Results [Published TrustNet - Apr 30 2014]
Amgen's net earnings dips by 25% to $1,073 mill... [Published PharmaBiz - Apr 23 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
Top 15 global pharma cos report disappointing r... [Published PharmaBiz - Mar 10 2014]
3-D printers make human tissue in push to creat... [Published Columbia Daily Herald - Mar 01 2014]
Prolia - Insurance [Published HealthBoards - Feb 15 2014]
Amgen net rises by 30% to $1,021 mn in Q4 [Published PharmaBiz - Jan 30 2014]
Amgen's net income moves up by 23.6% in Q3 [Published PharmaBiz - Oct 23 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Jul 11 2014]
Prolia - Insurance [Published HealthBoards - Feb 15 2014]
My husband and I are moving to the Tampa Bay, FL, area and I am insurance shopping. So far Humana has a couple plans that could work. Does anyone have experience with Humana paying for or not paying for Prolia injections? ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.